Actively Recruiting
RESET-MG Evaluating Autologous CD19-specific CAR T Cells CABA-201 for Safety and Effectiveness in Adults With Generalized Myasthenia Gravis
Led by Cabaletta Bio · Updated on 2026-10-19
24
Participants Needed
17
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of an investigational cell therapy called CABA-201 in adults with Generalized Myasthenia Gravis gMG, a rare autoimmune disorder causing muscle weakness due to problems in nerve-muscle communication. This study includes participants diagnosed with gMG who experience weakness in various muscle groups and aims to explore new treatment options as no cures currently exist. The trial is a Phase 12, open-label study sponsored by Cabaletta Bio focusing on this B-cell mediated autoimmune disease. Participants will receive a single intravenous infusion of CABA-201. Two approaches are being studied one with preconditioning using cyclophosphamide and fludarabine before the infusion, and another with escalating doses of CABA-201 given without preconditioning. The study groups include antibody-positive and antibody-negative cohorts. Each participant will receive only one dose during the treatment phase. Throughout the study, participants will be monitored for adverse events up to 28 days after infusion and then followed for up to 156 weeks to evaluate safety, pharmacodynamics, pharmacokinetics, biomarkers, and symptom changes measured by Myasthenia Gravis-specific scales such as MG-ADL, QMG, and MGC scores. Various assessments will be conducted over this period to track progress and treatment impact, ensuring comprehensive long-term evaluation and safety monitoring.
CONDITIONS
Brief Title
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Research Team
C
Cabaletta Bio
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here